

B1 (Official Form 1) (4/10)

UNITED STATES BANKRUPTCY COURT District of Massachusetts		VOLUNTARY PETITION							
Name of Debtor (if individual, enter Last, First, Middle): MOLECULAR INSIGHT PHARMACEUTICALS, INC.		Name of Joint Debtor (Spouse) (Last, First, Middle):							
All Other Names used by the Debtor in the last 8 years (include married, maiden, and trade names): Biostream, Inc.		All Other Names used by the Joint Debtor in the last 8 years (include married, maiden, and trade names):							
Last four digits of Soc. Sec. or Individual-Taxpayer I.D. (ITIN)/Complete EIN (if more than one, state all): 04-0562086		Last four digits of Soc. Sec. or Individual-Taxpayer I.D. (ITIN)/Complete EIN (if more than one, state all):							
Street Address of Debtor (No. and Street, City, and State): 160 Second Street Cambridge, MA ZIP CODE 02142		Street Address of Joint Debtor (No. and Street, City, and State): ZIP CODE							
County of Residence or of the Principal Place of Business: Middlesex		County of Residence or of the Principal Place of Business:							
Mailing Address of Debtor (if different from street address): ZIP CODE		Mailing Address of Joint Debtor (if different from street address): ZIP CODE							
Location of Principal Assets of Business Debtor (if different from street address above): ZIP CODE		Location of Principal Assets of Joint Debtor (if different from street address above): ZIP CODE							
Type of Debtor (Form of Organization) (Check one box.) <ul style="list-style-type: none"> <input type="checkbox"/> Individual (includes Joint Debtors) <i>See Exhibit D on page 2 of this form.</i> <input checked="" type="checkbox"/> Corporation (includes LLC and LLP) <input type="checkbox"/> Partnership <input type="checkbox"/> Other (If debtor is not one of the above entities, check this box and state type of entity below.) 	Nature of Business (Check one box.) <ul style="list-style-type: none"> <input type="checkbox"/> Health Care Business <input type="checkbox"/> Single Asset Real Estate as defined in 11 U.S.C. § 101(51B) <input type="checkbox"/> Railroad <input type="checkbox"/> Stockbroker <input type="checkbox"/> Commodity Broker <input type="checkbox"/> Clearing Bank <input checked="" type="checkbox"/> Other <hr/> Tax-Exempt Entity (Check box, if applicable.) <ul style="list-style-type: none"> <input type="checkbox"/> Debtor is a tax-exempt organization under Title 26 of the United States Code (the Internal Revenue Code). 	Chapter of Bankruptcy Code Under Which the Petition is Filed (Check one box.) <ul style="list-style-type: none"> <input type="checkbox"/> Chapter 7 <input type="checkbox"/> Chapter 9 <input checked="" type="checkbox"/> Chapter 11 <input type="checkbox"/> Chapter 12 <input type="checkbox"/> Chapter 13 <input type="checkbox"/> Chapter 15 Petition for Recognition of a Foreign Main Proceeding <input type="checkbox"/> Chapter 15 Petition for Recognition of a Foreign Nonmain Proceeding <hr/> Nature of Debts (Check one box.) <ul style="list-style-type: none"> <input type="checkbox"/> Debts are primarily consumer debts, defined in 11 U.S.C. § 101(8) as "incurred by an individual primarily for a personal, family, or household purpose." <input checked="" type="checkbox"/> Debts are primarily business debts. 							
Filing Fee (Check one box.) <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Full Filing Fee attached. <input type="checkbox"/> Filing Fee to be paid in installments (applicable to individuals only). Must attach signed application for the court's consideration certifying that the debtor is unable to pay fee except in installments. Rule 1006(b). See Official Form 3A. <input type="checkbox"/> Filing Fee waiver requested (applicable to chapter 7 individuals only). Must attach signed application for the court's consideration. See Official Form 3B. 		Chapter 11 Debtors <ul style="list-style-type: none"> Check one box: <ul style="list-style-type: none"> <input type="checkbox"/> Debtor is a small business debtor as defined in 11 U.S.C. § 101(51D). <input checked="" type="checkbox"/> Debtor is not a small business debtor as defined in 11 U.S.C. § 101(51D). Check if: <ul style="list-style-type: none"> <input type="checkbox"/> Debtor's aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$2,343,300 (amount subject to adjustment on 4/01/13 and every three years thereafter). Check all applicable boxes: <ul style="list-style-type: none"> <input type="checkbox"/> A plan is being filed with this petition. <input type="checkbox"/> Acceptances of the plan were solicited prepetition from one or more classes of creditors, in accordance with 11 U.S.C. § 1126(b). 							
Statistical/Administrative Information <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Debtor estimates that funds will be available for distribution to unsecured creditors. <input type="checkbox"/> Debtor estimates that, after any exempt property is excluded and administrative expenses paid, there will be no funds available for distribution to unsecured creditors. 									THIS SPACE IS FOR COURT USE ONLY
Estimated Number of Creditors <input type="checkbox"/> 1-49 <input checked="" type="checkbox"/> 50-99 <input type="checkbox"/> 100-199 <input type="checkbox"/> 200-999 <input type="checkbox"/> 1,000-5,000 <input type="checkbox"/> 5,001-10,000 <input type="checkbox"/> 10,001-25,000 <input type="checkbox"/> 25,001-50,000 <input type="checkbox"/> 50,001-100,000 <input type="checkbox"/> Over 100,000									
Estimated Assets <input type="checkbox"/> \$0 to \$50,000 <input type="checkbox"/> \$50,001 to \$100,000 <input type="checkbox"/> \$100,001 to \$500,000 <input type="checkbox"/> \$500,001 to \$1 million <input type="checkbox"/> \$1,000,001 to \$10 million <input checked="" type="checkbox"/> \$10,000,001 to \$50 million <input type="checkbox"/> \$50,000,001 to \$100 million <input type="checkbox"/> \$100,000,001 to \$500 million <input type="checkbox"/> \$500,000,001 to \$1 billion <input type="checkbox"/> More than \$1 billion									
Estimated Liabilities <input type="checkbox"/> \$0 to \$50,000 <input type="checkbox"/> \$50,001 to \$100,000 <input type="checkbox"/> \$100,001 to \$500,000 <input type="checkbox"/> \$500,001 to \$1 million <input type="checkbox"/> \$1,000,001 to \$10 million <input type="checkbox"/> \$10,000,001 to \$50 million <input type="checkbox"/> \$50,000,001 to \$100 million <input checked="" type="checkbox"/> \$100,000,001 to \$500 million <input type="checkbox"/> \$500,000,001 to \$1 billion <input type="checkbox"/> More than \$1 billion									

Voluntary Petition <i>(This page must be completed and filed in every case.)</i>		Name of Debtor(s): MOLECULAR INSIGHT PHARMACEUTICALS, INC.	
All Prior Bankruptcy Cases Filed Within Last 8 Years (If more than two, attach additional sheet.)			
Location Where Filed:	Case Number:	Date Filed:	
Location Where Filed:	Case Number:	Date Filed:	
Pending Bankruptcy Case Filed by any Spouse, Partner, or Affiliate of this Debtor (If more than one, attach additional sheet.)			
Name of Debtor:	Case Number:	Date Filed:	
District:	Relationship:	Judge:	
<p style="text-align: center;">Exhibit A</p> <p>(To be completed if debtor is required to file periodic reports (e.g., forms 10K and 10Q) with the Securities and Exchange Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and is requesting relief under chapter 11.)</p> <p><input checked="" type="checkbox"/> Exhibit A is attached and made a part of this petition.</p>		<p style="text-align: center;">Exhibit B</p> <p>(To be completed if debtor is an individual whose debts are primarily consumer debts.)</p> <p>I, the attorney for the petitioner named in the foregoing petition, declare that I have informed the petitioner that [he or she] may proceed under chapter 7, 11, 12, or 13 of title 11, United States Code, and have explained the relief available under each such chapter. I further certify that I have delivered to the debtor the notice required by 11 U.S.C. § 342(b).</p> <p>X _____ Signature of Attorney for Debtor(s) (Date)</p>	
Exhibit C			
Does the debtor own or have possession of any property that poses or is alleged to pose a threat of imminent and identifiable harm to public health or safety?			
<input type="checkbox"/> Yes, and Exhibit C is attached and made a part of this petition.			
<input checked="" type="checkbox"/> No.			
Exhibit D			
(To be completed by every individual debtor. If a joint petition is filed, each spouse must complete and attach a separate Exhibit D.)			
<input type="checkbox"/> Exhibit D completed and signed by the debtor is attached and made a part of this petition.			
If this is a joint petition:			
<input type="checkbox"/> Exhibit D also completed and signed by the joint debtor is attached and made a part of this petition.			
Information Regarding the Debtor - Venue (Check any applicable box.)			
<input checked="" type="checkbox"/> Debtor has been domiciled or has had a residence, principal place of business, or principal assets in this District for 180 days immediately preceding the date of this petition or for a longer part of such 180 days than in any other District.			
<input type="checkbox"/> There is a bankruptcy case concerning debtor's affiliate, general partner, or partnership pending in this District.			
<input type="checkbox"/> Debtor is a debtor in a foreign proceeding and has its principal place of business or principal assets in the United States in this District, or has no principal place of business or assets in the United States but is a defendant in an action or proceeding [in a federal or state court] in this District, or the interests of the parties will be served in regard to the relief sought in this District.			
Certification by a Debtor Who Resides as a Tenant of Residential Property (Check all applicable boxes.)			
<input type="checkbox"/> Landlord has a judgment against the debtor for possession of debtor's residence. (If box checked, complete the following.)			

(Name of landlord that obtained judgment)			

(Address of landlord)			
<input type="checkbox"/> Debtor claims that under applicable nonbankruptcy law, there are circumstances under which the debtor would be permitted to cure the entire monetary default that gave rise to the judgment for possession, after the judgment for possession was entered, and			
<input type="checkbox"/> Debtor has included with this petition the deposit with the court of any rent that would become due during the 30-day period after the filing of the petition.			
<input type="checkbox"/> Debtor certifies that he/she has served the Landlord with this certification. (11 U.S.C. § 362(l)).			

<p>Voluntary Petition (This page must be completed and filed in every case.)</p>	<p>Name of Debtor(s): MOLECULAR INSIGHT PHARMACEUTICALS, INC.</p>
Signatures	
<p style="text-align: center;">Signature(s) of Debtor(s) (Individual/Joint)</p> <p>I declare under penalty of perjury that the information provided in this petition is true and correct. [If petitioner is an individual whose debts are primarily consumer debts and has chosen to file under chapter 7] I am aware that I may proceed under chapter 7, 11, 12 or 13 of title 11, United States Code, understand the relief available under each such chapter, and choose to proceed under chapter 7. [If no attorney represents me and no bankruptcy petition preparer signs the petition] I have obtained and read the notice required by 11 U.S.C. § 342(b).</p> <p>I request relief in accordance with the chapter of title 11, United States Code, specified in this petition.</p> <p>X _____ Signature of Debtor</p> <p>X _____ Signature of Joint Debtor</p> <p>_____ Telephone Number (if not represented by attorney)</p> <p>_____ Date</p>	<p style="text-align: center;">Signature of a Foreign Representative</p> <p>I declare under penalty of perjury that the information provided in this petition is true and correct, that I am the foreign representative of a debtor in a foreign proceeding, and that I am authorized to file this petition.</p> <p>(Check only one box.)</p> <p><input type="checkbox"/> I request relief in accordance with chapter 15 of title 11, United States Code. Certified copies of the documents required by 11 U.S.C. § 1515 are attached.</p> <p><input type="checkbox"/> Pursuant to 11 U.S.C. § 1511, I request relief in accordance with the chapter of title 11 specified in this petition. A certified copy of the order granting recognition of the foreign main proceeding is attached.</p> <p>X _____ (Signature of Foreign Representative)</p> <p>_____ (Printed Name of Foreign Representative)</p> <p>_____ Date</p>
<p>X _____ Signature of Attorney*</p> <p>Signature of Attorney for Debtor(s) Alan L. Braunstein BBO #546042</p> <p>Printed Name of Attorney for Debtor(s) Riemer & Braunstein, LLP</p> <p>Firm Name Three Center Plaza Boston, Massachusetts 02108</p> <p>Address Tel: (617) 523-9000 Fax: (617) 880-3456</p> <p>Telephone Number 12/9/10</p> <p>_____ Date</p> <p><small>*In a case in which § 707(b)(4)(D) applies, this signature also constitutes a certification that the attorney has no knowledge after an inquiry that the information in the schedules is incorrect.</small></p>	<p style="text-align: center;">Signature of Non-Attorney Bankruptcy Petition Preparer</p> <p>I declare under penalty of perjury that: (1) I am a bankruptcy petition preparer as defined in 11 U.S.C. § 110; (2) I prepared this document for compensation and have provided the debtor with a copy of this document and the notices and information required under 11 U.S.C. §§ 110(b), 110(h), and 342(b); and, (3) if rules or guidelines have been promulgated pursuant to 11 U.S.C. § 110(h) setting a maximum fee for services chargeable by bankruptcy petition preparers, I have given the debtor notice of the maximum amount before preparing any document for filing for a debtor or accepting any fee from the debtor, as required in that section. Official Form 19 is attached.</p> <p>_____ Printed Name and title, if any, of Bankruptcy Petition Preparer</p> <p>_____ Social-Security number (If the bankruptcy petition preparer is not an individual, state the Social-Security number of the officer, principal, responsible person or partner of the bankruptcy petition preparer.) (Required by 11 U.S.C. § 110.)</p> <p>_____ Address</p> <p>X _____ Date</p> <p>Signature of bankruptcy petition preparer or officer, principal, responsible person, or partner whose Social-Security number is provided above.</p> <p>Names and Social-Security numbers of all other individuals who prepared or assisted in preparing this document unless the bankruptcy petition preparer is not an individual.</p> <p>If more than one person prepared this document, attach additional sheets conforming to the appropriate official form for each person.</p> <p><small>A bankruptcy petition preparer's failure to comply with the provisions of title 11 and the Federal Rules of Bankruptcy Procedure may result in fines or imprisonment or both. 11 U.S.C. § 110; 18 U.S.C. § 156.</small></p>
<p style="text-align: center;">Signature of Debtor (Corporation/Partnership)</p> <p>I declare under penalty of perjury that the information provided in this petition is true and correct, and that I have been authorized to file this petition on behalf of the debtor.</p> <p>The debtor requests the relief in accordance with the chapter of title 11, United States Code, specified in this petition.</p> <p>X _____ Signature of Authorized Individual Harry Stylli</p> <p>Printed Name of Authorized Individual President and Chief Restructuring Officer</p> <p>_____ Title of Authorized Individual</p> <p>_____ Date</p>	

B 1A (Official Form 1, Exhibit A) (9/97)

[If debtor is required to file periodic reports (e.g., forms 10K and 10Q) with the Securities and Exchange Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and is requesting relief under chapter 11 of the Bankruptcy Code, this Exhibit "A" shall be completed and attached to the petition.]

UNITED STATES BANKRUPTCY COURT

District of Massachusetts

In re Molecular Insight Pharmaceuticals, Inc.,) Case No. _____
 Debtor)
)
) Chapter 11

EXHIBIT "A" TO VOLUNTARY PETITION

1. If any of the debtor's securities are registered under Section 12 of the Securities Exchange Act of 1934, the SEC file number is 001-33284 .

2. The following financial data is the latest available information and refers to the debtor's condition on September 30, 2010* .

a. Total assets		\$	<u>36,453,000.00</u>	
b. Total debts (including debts listed in 2.c., below)		\$	<u>198,829,000.00</u>	
c. Debt securities held by more than 500 holders:				
				Approximate number of holders:
secured <input type="checkbox"/>	unsecured <input type="checkbox"/>	subordinated <input type="checkbox"/>	\$ _____	_____
secured <input type="checkbox"/>	unsecured <input type="checkbox"/>	subordinated <input type="checkbox"/>	\$ _____	_____
secured <input type="checkbox"/>	unsecured <input type="checkbox"/>	subordinated <input type="checkbox"/>	\$ _____	_____
secured <input type="checkbox"/>	unsecured <input type="checkbox"/>	subordinated <input type="checkbox"/>	\$ _____	_____
secured <input type="checkbox"/>	unsecured <input type="checkbox"/>	subordinated <input type="checkbox"/>	\$ _____	_____
d. Number of shares of preferred stock			_____	_____
e. Number of shares common stock			<u>25,268,327</u>	_____

Comments, if any: _____

* The unaudited financial data contained herein is part of the Form 10-Q filed with the Securities and Exchange Commission on November 4, 2010.

3. Brief description of debtor's business: _____

Molecular Insight Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for oncology and cardiology use.

4. List the names of any person who directly or indirectly owns, controls, or holds, with power to vote, 5% or more of the voting securities of debtor: _____

Refer to Schedule 1

Schedule 1 - Equity Security Holders Holding 5% or More

The following directly or indirectly own, control, or hold, with power to vote, 5% or more of the voting securities of the debtor:

Cerberus Partners, L.P.
Highland Capital Management, L.P.
QVT Financial LP
Savitr Capital, LLC
James Poitras
David S. Barlow

MOLECULAR INSIGHT PHARMACEUTICALS, INC.

CERTIFICATE OF RESOLUTIONS

December 8, 2010

I, Harry Stylli, President and Chief Restructuring Officer of Molecular Insight Pharmaceuticals, Inc. (the "Company"), a Massachusetts corporation, certify that the following resolutions were duly adopted at the December 8, 2010 meeting of the board of directors of the Company (the "Board") in accordance with the requirements of applicable Massachusetts law and that said resolutions have not been modified or rescinded and are still in full force and effect on the date hereof:

WHEREAS, the Board has considered the financial and operational aspects of the Company's business;

WHEREAS, the Board has reviewed the historical performance of the Company, the market for the Company's products and the current and long-term liabilities of the Company;

WHEREAS, the Board has reviewed the proposed terms of that certain Investment Agreement (the "Investment Agreement"), by and between the Company and Savitr Capital LLC ("Savitr") pursuant to which the reorganized Company, as reorganized on the effective date of a plan of reorganization in accordance with the terms set forth therein, will issue to Savitr 100,000,000 shares of common stock, par value \$0.01 per share, representing 90% of the total equity capital of the reorganized Company on a fully diluted basis in exchange for an aggregate purchase price of \$45,000,000; and

WHEREAS, the Board has evaluated the Company's alternatives in connection with a possible restructuring and has determined that the filing of a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") is in the best interests of the Company and its creditors.

NOW, THEREFORE, BE IT,

RESOLVED, that the form, terms, and conditions of the Investment Agreement, and the transactions contemplated thereby, be, and they hereby are, authorized, approved and adopted; and it is further

RESOLVED, that the Company file a voluntary petition in bankruptcy under chapter 11 of the Bankruptcy Code and cause the same to be filed in the United States Bankruptcy Court for the District of Massachusetts (the "Bankruptcy Court") at such time as the Authorized Officer (as defined below) executing such petition shall determine; and it is further

RESOLVED, that the appointment of (i) Kramer Levin Naftalis & Frankel LLP, as lead bankruptcy counsel, (ii) Riemer & Braunstein, LLP, as local Massachusetts bankruptcy counsel, (iii) Foley & Lardner LLP, as special counsel, (iv) CRT Capital Group LLC, as financial advisor, and (v) Tatum LLC, a division of SFN Professional Services LLC ("Tatum"), as financial consultant and Mark A. Attarian as Interim Executive Vice President and Chief Financial

Officer, be and hereby are ratified, approved, confirmed and adopted; and it is further

RESOLVED, that the president, chief executive officer, chief financial officer, the chief restructuring officer, any senior vice president, any executive vice president, any vice president, the secretary, and the treasurer of the Company (each, an "Authorized Officer") be, and each of them, acting alone, hereby is, authorized, empowered and directed, in the name and on behalf of the Company, to execute and verify a petition under chapter 11 of the Bankruptcy Code with respect to the Company and to cause the same to be filed in the Bankruptcy Court at such time as the Authorized Officer executing such petition shall determine; and it is further

RESOLVED, that the Authorized Officers shall be, and each of them, acting alone, hereby is, authorized, empowered and directed to execute and approve the filing of all schedules, motions, lists, applications, pleadings and other papers and, in connection therewith, to employ and retain all assistance by legal counsel, accountants, financial advisors and other professionals including, without limitation, Kramer Levin Naftalis & Frankel LLP, Riemer & Braunstein, LLP, Foley & Lardner LLP, Tatum and CRT Capital Group LLC, subject to the approval of the Bankruptcy Court, and to take and perform any and all such further acts and deeds that any such Authorized Officer deems necessary and proper in connection with the Company's chapter 11 case (the "Chapter 11 Case"), with a view to the successful prosecution of such case; and it is further


RESOLVED, that in connection with the commencement of the Chapter 11 Case by the Company, the Authorized Officers shall be, and each of them, acting alone, hereby is, authorized and empowered, in the name of and on behalf of the Company, to negotiate, agree to, and seek entry in the Bankruptcy Court of an order approving the Company's use of cash collateral, upon substantially the terms described to the Board or upon such additional or other terms as such Authorized Officer determines to be necessary or appropriate; and it is further

RESOLVED, that, in addition to the specific authorizations heretofore conferred upon the Authorized Officers, the Authorized Officers, and such other officers of the Company as any Authorized Officer shall from time to time designate, and any employees or agents (including the Company's legal counsel) designated by or directed by any Authorized Officer, be, and each hereby is, authorized, empowered and directed, in the name and on behalf of the Company to enter into, execute, deliver, acknowledge, certify, file and/or record, and perform such agreements, instruments, motions, affidavits, applications for approvals or rulings of governmental or regulatory authorities, certificates or other documents and to pay all expenses, including filing fees, and to take such other actions, as in the judgment of any Authorized Officer shall be or become necessary, proper or desirable to the successful prosecution of the Chapter 11 Case; and it is further

RESOLVED, that any and all past lawful actions heretofore taken by any Authorized Officer or the directors of the Company in the name and on behalf of the Company, in furtherance of any or all of the preceding resolutions be, and the same hereby are, ratified, confirmed and approved.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, this Certificate has been signed and shall be effective as of the date first written above.



By: Harry Stylli
Title: President and Chief Restructuring
Officer

Form B4 (Official Form 4) - (12/07)

Molecular Insight Pharmaceuticals, Inc.

Debtor

Case No. (if known)

Form 4. LIST OF CREDITORS HOLDING 20 LARGEST UNSECURED CLAIMS

UNITED STATES BANKRUPTCY COURT

DISTRICT OF MASSACHUSETTS

Following is a list of the debtor's creditors holding the 20 largest unsecured claims. The list is prepared in accordance with Fed. R. Bankr. P. 1007(d) for filing in this chapter 11 [or chapter 9] case. The list does not include (1) persons who come within the definition of "insider" set forth in 11 U.S.C. § 101, or (2) secured creditors unless the value of the collateral is such that the unsecured deficiency places the creditor among the holders of the 20 largest unsecured claims. If a minor child is one of the creditors holding the 20 largest unsecured claims, state the child's initials and the name and address of the child's parent or guardian, such as "A.B., a minor child, by John Doe, guardian." Do not disclose the child's name. See 11 U.S.C. § 112 and Fed. R. Bankr. P. 1007(m).

Name of creditor and complete mailing address, including zip code.	Name, telephone number and complete mailing address, including zip code, of employee, agent, or department of creditor familiar with claim who may be contacted	Nature of claim (trade debt, bank loan, government contract, etc.)	CONTINGENT	UNLIQUIDATED	DISPUTED	AMOUNT OF CLAIM (if secured also state value of security)
1 JOHN MCCRAY 635 RESERVOIR ROAD PO BOX 1275 EAST OTIS, MA 01029	JOHN MCCRAY 635 RESERVOIR ROAD PO BOX 1275 EAST OTIS, MA 01029 TEL: 413-269-7648	SEVERANCE			X	\$162,500.00
2 INC RESEARCH, INC. ATTN: ACCOUNTS RECEIVABLE DEPARTMENT 75 REMITTANCE DRIVE SUITE 3160 CHICAGO, IL 60675-3160	INC RESEARCH, INC. ATTN: ACCOUNTS RECEIVABLE DEPARTMENT 75 REMITTANCE DRIVE SUITE 3160 CHICAGO, IL 60675-3160 TEL: 919-876-9300 FAX: 919-876-9360	TRADE				\$34,126.00
3 PPD DEVELOPMENT, LP ATTN: DAVID CROWE 12937 COLLECTIONS CENTER DRIVE CHICAGO, IL 60693	PPD DEVELOPMENT, LP ATTN: DAVID CROWE 12937 COLLECTIONS CENTER DRIVE CHICAGO, IL 60693 TEL: 512-747-5382 FAX: 512-747-5386	TRADE				\$27,601.97
4 MASTER CONTROLS, INC. 6322 SOUTH 3000 EAST SUITE 110 SALT LAKE CITY, UT 84121	MASTER CONTROLS, INC. 6322 SOUTH 3000 EAST SUITE 110 SALT LAKE CITY, UT 84121 TEL: 801-942-4000	TRADE				\$26,162.07

Form B4 (Official Form 4) - (12/07)

Molecular Insight Pharmaceuticals, Inc.

Debtor

Case No. (If known)

Form 4. LIST OF CREDITORS HOLDING 20 LARGEST UNSECURED CLAIMS
(Continuation Sheet)

Name of creditor and complete mailing address, including zip code.	Name, telephone number and complete mailing address, including zip code, of employee, agent, or department of creditor familiar with claim who may be contacted	Nature of claim (trade debt, bank loan, government contract, etc.)	CONTINGENT	UNLIQUIDATED	DISPUTED	AMOUNT OF CLAIM (if secured also state value of security)
5 DOBBS CONSULTING, LLC ATTN: BROOKE LOZIER 454 BEECHWOOD CIRCLE BURNS, TN 37029-9057	DOBBS CONSULTING, LLC ATTN: BROOKE LOZIER 454 BEECHWOOD CIRCLE BURNS, TN 37029-9057 TEL: 703-904-4335	TRADE				\$22,740.34
6 CORELAB PARTNERS, INC. ATTN: DANIELLE LOMBARDO 100 OVERLOOK CENTER PRINCETON, NJ 08540	CORELAB PARTNERS, INC. ATTN: DANIELLE LOMBARDO 100 OVERLOOK CENTER PRINCETON, NJ 08540 TEL: 609-936-2600 FAX: 609-936-2602	TRADE				\$20,267.97
7 UNIVERSITY OF IOWA GRANT ACCOUNTING OFFICE B5 JESSUP HALL IOWA CITY, IA 52242	UNIVERSITY OF IOWA GRANT ACCOUNTING OFFICE B5 JESSUP HALL IOWA CITY, IA 52242 TEL: 319-335-3801 FAX: 319-335-0674	TRADE			X	\$15,788.00
8 ERESEARCH TECHNOLOGY ATTN: STACEY L. FERRANO, DIRECTOR CONTRACTS AND PROPOSALS 30 SOUTH 17TH STREET, 8TH FLOOR PHILADELPHIA, PA 19103	ERESEARCH TECHNOLOGY ATTN: STACEY L. FERRANO, DIRECTOR CONTRACTS AND PROPOSALS 30 SOUTH 17TH STREET, 8TH FLOOR PHILADELPHIA, PA 19103 TEL: 215-972-0420 FAX: 215-972-0414	TRADE				\$7,639.80
9 BIOCLINICA, INC. 800 ADAMS AVENUE SUITE 201 AUDUBON, PA 19403	BIOCLINICA, INC. 800 ADAMS AVENUE SUITE 201 AUDUBON, PA 19403	TRADE				\$7,250.00
10 CAMBRIDGE SCIENTIFIC PRODUCTS 26 NEW STREET CAMBRIDGE, MA 02138	CAMBRIDGE SCIENTIFIC PRODUCTS 26 NEW STREET CAMBRIDGE, MA 02138 TEL: 617-354-8900 FAX: 617-924-3018	TRADE				\$5,075.00

Form B4 (Official Form 4) - (12/07)

Molecular Insight Pharmaceuticals, Inc.

Debtor

Case No. (if known)

**Form 4. LIST OF CREDITORS HOLDING 20 LARGEST UNSECURED CLAIMS
(Continuation Sheet)**

Name of creditor and complete mailing address, including zip code.	Name, telephone number and complete mailing address, including zip code, of employee, agent, or department of creditor familiar with claim who may be contacted	Nature of claim (trade debt, bank loan, government contract, etc.)	STATUS			AMOUNT OF CLAIM (if secured also state value of security)
			CONTINGENT	UNLIQUIDATED	DISPUTED	
11 RADIATION DOSIMETRY SYSTEMS INC. ATTN: JAMES STUBBS 1003 CERRITO WAY PALO ALTO, CA 94306	RADIATION DOSIMETRY SYSTEMS INC. ATTN: JAMES STUBBS 1003 CERRITO WAY PALO ALTO, CA 94306 TEL: 678-575-5100	TRADE				\$5,000.00
12 AT&T PO BOX 5019 CAROL STREAM, IL 60197	AT&T PO BOX 5019 CAROL STREAM, IL 60197 TEL: 800- 847-3595	TRADE				\$4,529.78
13 KONICA MINOLTA BUSINESS SOLUTIONS PO BOX 403718 ATLANTA, GA 30384	KONICA MINOLTA BUSINESS SOLUTIONS PO BOX 403718 ATLANTA, GA 30384 TEL: 973-812-1800	TRADE				\$4,467.63
14 CITY OF DENTON 221 NORTH ELM DENTON, TX 76201	CITY OF DENTON 221 NORTH ELM DENTON, TX 76201	UTILITY				\$4,315.28
15 RR DONNELLY ATTN: BRIAN BYRNE PO BOX 13654 NEWARK, NJ 07188	RR DONNELLY ATTN: BRIAN BYRNE PO BOX 13654 NEWARK, NJ 07188 TEL: 313-326-8000 FAX: 617-345-4543	TRADE				\$4,102.00
16 PHENOMENEX PO BOX 749397 LOS ANGELES, CA 90074	PHENOMENEX PO BOX 749397 LOS ANGELES, CA 90074 TEL: 310-212-0555 FAX: 310-328-7768	TRADE				\$3,010.25

Form B4 (Official Form 4) - (12/07)

Molecular Insight Pharmaceuticals, Inc.

Debtor

Case No. (If known)

Form 4. LIST OF CREDITORS HOLDING 20 LARGEST UNSECURED CLAIMS
(Continuation Sheet)

Name of creditor and complete mailing address, including zip code.	Name, telephone number and complete mailing address, including zip code, of employee, agent, or department of creditor familiar with claim who may be contacted	Nature of claim (trade debt, bank loan, government contract, etc.)	CONTINGENT	UNLIQUIDATED	DISPUTED	AMOUNT OF CLAIM (if secured also state value of security)
17 DUBLIN LAB SERVICES PO BOX 227 BURLINGTON, MA 01803	DUBLIN LAB SERVICES PO BOX 227 BURLINGTON, MA 01803 TEL: 617-320-8036	TRADE				\$3,000.00
18 TIMOTHY LARGEN 1411 GREENWOOD DRIVE DENTON, TX 76209	TIMOTHY LARGEN 1411 GREENWOOD DRIVE DENTON, TX 76209	TRADE				\$2,820.00
19 TACONIC FARMS, INC. 450 PARK AVENUE, 9TH FLOOR NEW YORK, NY 10022	TACONIC FARMS, INC. 450 PARK AVENUE, 9TH FLOOR NEW YORK, NY 10022 TEL: 518-697-3900	TRADE				\$2,646.00
20 PREVALERE LIFE SCIENCES 8282 HALSEY ROAD WHITESBORO, NY 13492	PREVALERE LIFE SCIENCES 8282 HALSEY ROAD WHITESBORO, NY 13492 TEL: 315-768-2500 FAX: 315-763-2460	TRADE				\$2,268.87

THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF MASSACHUSETTS
(EASTERN DIVISION)

In re:

MOLECULAR INSIGHT
PHARMACEUTICALS, INC.,¹

Debtor.

Chapter 11

Case No. 10- _____ ()

**CERTIFICATION CONCERNING LIST OF CREDITORS
HOLDING 20 LARGEST UNSECURED CLAIMS**

The above-captioned debtor and debtor in possession (the "Debtor"), hereby certifies under penalty of perjury that the *List of Creditors Holding 20 Largest Unsecured Claims*, submitted herewith, is complete and to the best of the Debtor's knowledge correct and consistent with Debtor's books and records as of ^{December} ~~November~~ 9, 2010.

The information contained herein is based upon a review of the Debtor's books and records. However, no comprehensive legal and/or factual investigations with regard to possible defenses to any claims set forth in the *List of Creditors Holding 20 Largest Unsecured Claims* have been completed. Therefore, the listing does not and should not be deemed to constitute: (1) waiver of any defense to any listed claims; (2) an acknowledgement of the allowability of any list claims; and/or (3) a waiver of any other right or legal position of the Debtor.

I declare under penalty of perjury that the foregoing is true and correct.

Executed this 9th day of December, 2010.



Harry Stylli
President and Chief Restructuring Officer

¹ The last four digits of the Debtor's tax identification number are 2086.